Navigation Links
Mast Therapeutics Announces Positive Data In Model Of Heart Failure
Date:1/6/2014

>Details of the Study and Results
The objective of the study was to determine the effect of acute intravenous administration of MST-188 on left ventricular systolic and diastolic cardiac function in a model of chronic heart failure produced by multiple sequential intracoronary microembolizations.  A single dose of MST-188 (low or high dose) or placebo was administered over 2 hours.  Hemodynamic, ventriculographic, echocardiographic and electrocardiographic measurements were taken at baseline (prior to study drug administration) and at the following time-points after the start of study drug administration: 2 hours (end of administration), 24 hours, 1 week and 2 weeks.  Peripheral venous blood samples were obtained at the same time-points.  The improvements described above were calculated as the difference between baseline and mean values of each study group at each time-point using a one-way analysis of variance, with p<0.05 considered significant.  The study was conducted under the supervision of Dr. Hani N. Sabbah at Henry Ford Health System, a Michigan non-profit corporation. 

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs.  MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow).&#
'/>"/>

SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SAN DIEGO , Aug. 29, 2014 /PRNewswire/ ... an emerging biopharmaceutical company, announced today that Santosh ... will be leaving the Company, for personal reasons, ... the Chief Medical Officer of Aires Pharmaceuticals, which ... Vetticaden,s former responsibilities as the Company,s interim Chief ...
(Date:8/29/2014)... 2014 Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... Stanley Global Healthcare Conference on Wednesday, September 10. ... Executive Officer, will provide an update on the company, ... Pacific Daylight Time).   A webcast of ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... and WALTHAM, Mass., May 25, 2011 Interleukin Genetics, Inc. ... USP Hospitales now offers the innovative Heart Health Genetic ... Hospitales, the flagship hospital in Madrid, and will soon ... identifies single nucleotide variations in two Interleukin-1 (IL-1) genes ...
... May 25, 2011 Cambridge Temperature Concepts (CTC), ... has been awarded an I Award by the Wireless-Life ... to solving healthcare challenges . DuoFertility uses wireless technology to ... a baby the best possible chance of conceiving naturally. News ...
Cached Medicine Technology:USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 2USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 3USP Hospitales of Spain to Offer Interleukin Genetics' Heart Health Test Throughout Its Hospital Network 4Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility 2Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility 3Cambridge Temperature Concepts Wins Prestigious Award From the Wireless-Life Sciences Alliance for Fertility Monitor DuoFertility 4
(Date:8/29/2014)... Angeles, CA (PRWEB) August 29, 2014 ... inspired others who talked about introducing these cutting ... experience as chairman of the FUE Research Committee has ... studies that redefine what is possible with modern technology. ... of a variety of FUE devices that facilitate extraction ...
(Date:8/29/2014)... 2014 According to a CNN article, ... (8/25), a new study found that those states ... seen a significant decrease in the number of painkiller ... ten year period, and comparing various states with and ... that there was about a 25% decrease in painkiller ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by ... Monitoring For Drug Abuse Trends , Outbreaks (8/20), the National ... attempt to monitor drug abuse trends by turning to social ... drug abuse trends, it is also working with the University ... National Drug Early Warning System, which will be funded by ...
(Date:8/29/2014)... An article entitled How Genes, Gender and ... explains how genes, gender and the environment that an individual ... drugs. Researchers at Indiana University are taking another look at ... and are applying this factor to what is known about ... family and community ties can help to reduce a man’s ...
(Date:8/29/2014)... 29, 2014 Healthpointe is proud to ... Dr. Rodas will be practicing out of Healthpointe’s newest ... member of Healthpointe’s orthopedic team, Dr. Rodas ... and board-certified in occupational medicine. , Among Dr. ... Medical Director of Raytheon, the world-class defense and aerospace ...
Breaking Medicine News(10 mins):Health News:Parsa Mohebi M.D., Beverly Hills Hair Restoration Surgeon Gives Inspiring Lecture on Groundbreaking Techniques in Follicular Unit Extraction 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 3Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Substance Abuse Likelihood Affected by Environment, Gender and Genes 2Health News:Substance Abuse Likelihood Affected by Environment, Gender and Genes 3Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2
... in necessary prescriptions, study finds , , TUESDAY, Feb. 3 ... "doughnut hole" in the Medicare Part D drug plan ... with an employer-based plan, a new study finds. , ... costs from hospitalizations and doctor visits resulting from this ...
... Ala. Exposure to second-hand smoke and alcohol significantly ... at the University of Alabama at Birmingham (UAB). , ... and alcohol are worse for health as a combination, ... an associate professor in the UAB Department of Environmental ...
... Group, Inc.,(NYSE Alternext US: QGP) ( www.QuantumMD.com ) announced ... debut at the 2009 Pri-Med,South Conference and Expo alongside ... Quantum believes PWeR is the next generation in healthcare ... Obama is calling for within,the industry. Pete Martinez, ...
... A thesis from the Sahlgrenska Academy, University of Gothenburg, ... suicide attempt are five times more likely to attempt ... nightmares. , The study included 165 patients aged ... psychiatric departments following a suicide attempt in Sweden. Psychiatric ...
... Feb. 3 Physicians have been raving about the ... 2008 survey of U.S. VASER Lipo physicians, 95% of ... physician or facility. The VASER Lipo System ... contouring applications from precise sculpting to significant fat removal."Hundreds ...
... improve writing skills for those with aphasia with the aid ... doctoral thesis from the Sahlgrenska Academy at the University of ... use spoken language, and the ability to read and write. ... writing aids in the study on which speech and language ...
Cached Medicine News:Health News:Medicare Drug Plan 'Doughnut Hole' Could Impact Seniors' Health 2Health News:Tobacco smoke and alcohol harm liver worse as combo 2Health News:PWeR(TM) Introduced at Regional Healthcare Conference 2Health News:PWeR(TM) Introduced at Regional Healthcare Conference 3Health News:PWeR(TM) Introduced at Regional Healthcare Conference 4Health News:Nightmares increase risk of further suicide attempts 2Health News:THE RESULTS ARE IN! VASER(R) Lipo Receives 95% Approval Rating by Physician Users 2Health News:Computerized writing aids make writing easier for persons with aphasia 2
... segment surgical procedures. For dissection of vitreoretinal ... luer lock tubing set is attached to ... - .02in (.50mm); OD - .06in (1.5mm) ... viscoelastic fluids. 30G (.30mm) tip, flattened. Angled ...
Product designed specifically for posteror segment surgical procedures. Facilitates posterior segment infusion. Flexible tubing 10in (25cm)....
For surgical treatment, repair and irrigation of the nasolacrimal system. Silicone tubing. Length 14in (35cm) ID: .012in (.30mm) OD: .025in (.60mm)...
...
Medicine Products: